FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2034983264> ?p ?o ?g. }

• W2034983264 endingPage "1938" @default.
• W2034983264 startingPage "1929" @default.
• W2034983264 abstract "Malignant melanoma is a highly aggressive cancer, and the incidence of this disease is increasing worldwide at an alarming rate. Despite advances in the treatment of melanoma, patients with metastatic disease still have a poor prognosis and low survival rate. New strategies, including targeted radiotherapy, would provide options for patients who become resistant to therapies such as BRAF inhibitors. Very late antigen-4 (VLA-4) is expressed on melanoma tumor cells in higher levels in more aggressive and metastatic disease and may provide an ideal target for drug delivery and targeted radiotherapy. In this study, we evaluated (177)Lu- and (68)Ga-labeled DOTA-PEG4-LLP2A as a VLA-4-targeted radiotherapeutic with a companion PET agent for diagnosis and monitoring metastatic melanoma treatment. DOTA-PEG4-LLP2A was synthesized by solid-phase synthesis. The affinity of (177)Lu- and (68)Ga-labeled DOTA-PEG4-LLP2A to VLA-4 was determined in B16F10 melanoma cells by saturation binding and competitive binding assays, respectively. Biodistribution of the LLP2A conjugates was determined in C57BL/6 mice bearing B16F10 subcutaneous tumors, while PET/CT imaging was performed in subcutaneous and metastatic models. (177)Lu-DOTA-PEG4-LLP2A showed high affinity to VLA-4 with a Kd of 4.1 ± 1.5 nM and demonstrated significant accumulation in the B16F10 melanoma tumor after 4 h (31.5 ± 7.8%ID/g). The tumor/blood ratio of (177)Lu-DOTA-PEG4-LLP2A was highest at 24 h (185 ± 26). PET imaging of metastatic melanoma with (68)Ga-DOTA-PEG4-LLP2A showed high uptake in sites of metastases and correlated with bioluminescence imaging of the tumors. These data demonstrate that (177)Lu-DOTA-PEG4-LLP2A has potential as a targeted therapeutic for treating melanoma as well as other VLA-4-expressing tumors. In addition, (68)Ga-DOTA-PEG4-LLP2A is a readily translatable companion PET tracer for imaging of metastatic melanoma." @default.
• W2034983264 created "2016-06-24" @default.
• W2034983264 creator A5002367405 @default.
• W2034983264 creator A5036637525 @default.
• W2034983264 creator A5066132044 @default.
• W2034983264 date "2015-05-08" @default.
• W2034983264 modified "2023-10-08" @default.
• W2034983264 title "Evaluation of ⁶⁸Ga- and ¹⁷⁷Lu-DOTA-PEG₄-LLP2A for VLA-4-Targeted PET Imaging and Treatment of Metastatic Melanoma" @default.
• W2034983264 cites W100113983 @default.
• W2034983264 cites W120982652 @default.
• W2034983264 cites W134493433 @default.
• W2034983264 cites W1971947883 @default.
• W2034983264 cites W1983902360 @default.
• W2034983264 cites W1991993823 @default.
• W2034983264 cites W1997987445 @default.
• W2034983264 cites W2005389389 @default.
• W2034983264 cites W2005674134 @default.
• W2034983264 cites W2011540855 @default.
• W2034983264 cites W2011732158 @default.
• W2034983264 cites W2018233092 @default.
• W2034983264 cites W2040471046 @default.
• W2034983264 cites W2040851929 @default.
• W2034983264 cites W2045205459 @default.
• W2034983264 cites W2045944156 @default.
• W2034983264 cites W2049089156 @default.
• W2034983264 cites W2052313621 @default.
• W2034983264 cites W2052781279 @default.
• W2034983264 cites W2066717393 @default.
• W2034983264 cites W2087855741 @default.
• W2034983264 cites W2091100650 @default.
• W2034983264 cites W2091274667 @default.
• W2034983264 cites W2097995306 @default.
• W2034983264 cites W2101395524 @default.
• W2034983264 cites W2101990345 @default.
• W2034983264 cites W2107385057 @default.
• W2034983264 cites W2114565243 @default.
• W2034983264 cites W2128542677 @default.
• W2034983264 cites W2133817804 @default.
• W2034983264 cites W2135480474 @default.
• W2034983264 cites W2138600064 @default.
• W2034983264 cites W2140985303 @default.
• W2034983264 cites W2148617171 @default.
• W2034983264 cites W2153216820 @default.
• W2034983264 cites W2153881254 @default.
• W2034983264 cites W2154755646 @default.
• W2034983264 cites W2164918836 @default.
• W2034983264 cites W2166262263 @default.
• W2034983264 cites W2284510743 @default.
• W2034983264 cites W2308365376 @default.
• W2034983264 cites W2572174216 @default.
• W2034983264 cites W4241605155 @default.
• W2034983264 cites W4243065089 @default.
• W2034983264 cites W4255370270 @default.
• W2034983264 cites W52103172 @default.
• W2034983264 doi "https://doi.org/10.1021/mp5006917" @default.
• W2034983264 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5167571" @default.
• W2034983264 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25919487" @default.
• W2034983264 hasPublicationYear "2015" @default.
• W2034983264 type Work @default.
• W2034983264 sameAs 2034983264 @default.
• W2034983264 citedByCount "37" @default.
• W2034983264 countsByYear W20349832642016 @default.
• W2034983264 countsByYear W20349832642017 @default.
• W2034983264 countsByYear W20349832642018 @default.
• W2034983264 countsByYear W20349832642019 @default.
• W2034983264 countsByYear W20349832642020 @default.
• W2034983264 countsByYear W20349832642021 @default.
• W2034983264 countsByYear W20349832642022 @default.
• W2034983264 countsByYear W20349832642023 @default.
• W2034983264 crossrefType "journal-article" @default.
• W2034983264 hasAuthorship W2034983264A5002367405 @default.
• W2034983264 hasAuthorship W2034983264A5036637525 @default.
• W2034983264 hasAuthorship W2034983264A5066132044 @default.
• W2034983264 hasBestOaLocation W20349832642 @default.
• W2034983264 hasConcept C126322002 @default.
• W2034983264 hasConcept C185592680 @default.
• W2034983264 hasConcept C202751555 @default.
• W2034983264 hasConcept C2777658100 @default.
• W2034983264 hasConcept C2777807558 @default.
• W2034983264 hasConcept C2989005 @default.
• W2034983264 hasConcept C502942594 @default.
• W2034983264 hasConcept C509974204 @default.
• W2034983264 hasConcept C55493867 @default.
• W2034983264 hasConcept C71924100 @default.
• W2034983264 hasConceptScore W2034983264C126322002 @default.
• W2034983264 hasConceptScore W2034983264C185592680 @default.
• W2034983264 hasConceptScore W2034983264C202751555 @default.
• W2034983264 hasConceptScore W2034983264C2777658100 @default.
• W2034983264 hasConceptScore W2034983264C2777807558 @default.
• W2034983264 hasConceptScore W2034983264C2989005 @default.
• W2034983264 hasConceptScore W2034983264C502942594 @default.
• W2034983264 hasConceptScore W2034983264C509974204 @default.
• W2034983264 hasConceptScore W2034983264C55493867 @default.
• W2034983264 hasConceptScore W2034983264C71924100 @default.
• W2034983264 hasFunder F4320306084 @default.
• W2034983264 hasFunder F4320337351 @default.
• W2034983264 hasIssue "6" @default.
• W2034983264 hasLocation W20349832641 @default.

• next